Adaptor protein complex 1 (AP-1) is an evolutionary conserved heterotetramer that promotes vesicular trafficking between the trans-Golgi network and the endosomes. The knockout of most murine AP-1 complex subunits is embryonically lethal, so the identification of human disease-associated alleles has the unique potential to deliver insights into gene function. Here, we report two founder mutations (c.11T>G [p.Phe4Cys] and c.97C>T [p.Arg33Trp]) in AP1S3, the gene encoding AP-1 complex subunit s1C, in 15 unrelated individuals with a severe autoinflammatory skin disorder known as pustular psoriasis. Because the variants are predicted to destabilize the 3D structure of the AP-1 complex, we generated AP1S3-knockdown cell lines to investigate the consequences of AP-1 deficiency in skin keratinocytes. We found that AP1S3 silencing disrupted the endosomal translocation of the innate pattern-recognition receptor TLR-3 (Toll-like receptor 3) and resulted in a marked inhibition of downstream signaling. These findings identify pustular psoriasis as an autoinflammatory phenotype caused by defects in vesicular trafficking and demonstrate a requirement of AP-1 for Toll-like receptor homeostasis.
involved in the transport of cargoes between the trans-Golgi network and the endosomes, a process that requires the formation of specialized clathrin-coated vesicles. Similar to other AP complexes, AP-1 consists of two large (g and b1), one medium (m1), and one small (s1) subunit. These are the product of eight genes, which encode multiple isoforms of the b1 (b1A and b1B), m1 (m1A and m1B), and s1 (s1A, s1B, and s1C) subunits. 2 Of note, the knockout of genes encoding the murine AP-1 g and m1A subunits is embryonically lethal. 3 Although this observation underscores the crucial role of AP-1 in cell homeostasis, it also highlights the difficulty of investigating its function in vivo. The term pustular psoriasis indicates a group of rare and severe inflammatory skin disorders that often manifest with concomitant plaque psoriasis. Generalized pustular psoriasis (GPP [MIM 614204]) is the most severe form of the disease and is characterized by acute, potentially life-threatening episodes of skin pustulation and systemic inflammation. Conversely, palmar plantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH) are chronic, localized, and disabling conditions that affect the palms and soles (PPP) or the tips of the fingers and toes (ACH). 4 We and others have identified recessive mutations in IL36RN (MIM 605507), the gene encoding IL-36 receptor antagonist, in individuals affected by GPP, ACH, and PPP, thus demonstrating a shared genetic basis for acute and chronic forms of pustular psoriasis. [5] [6] [7] Importantly, IL36RN defects are only found in a minority of affected individuals, 8 an observation that underscores our limited understanding of disease pathogenesis. Here, we report the identification of pustular psoriasis mutations in AP1S3 (RefSeq accession number NM_ 001039569.1), the gene encoding the s1C subunit of the AP-1 complex.
We undertook the search for disease-causing mutations by means of whole-exome sequencing. To minimize the confounding effects of genetic heterogeneity, we focused on a single disease subtype and examined seven isolated ACH subjects (individuals S0655-S0661 in Table 1 ; Figure 1A ). The study was approved by the research ethics committees of the contributing institutions, and all participants granted their written informed consent. Wholeexome capture was carried out with the Agilent Sure Select XT Human All Exome Kit (v.4), and enriched DNA fragments were sequenced on an Illumina HiSeq2000 apparatus. Paired-end reads were aligned to the hg19 reference genome (UCSC Genome Browser) with Novoalign (v.2.07.17, Novocraft Technologies). Over 8.2 Gb of sequence was obtained for each subject, so that >90% of Gencode bases were covered at a depth exceeding 203 (Table S1 , available online). Single-nucleotide substitutions and small indels were identified with Samtools (v.0.1.18) 10 and annotated to coding genes with the ANNOVAR package (October 2012 release). 11 The variant profiles thus generated were merged with those of two individuals affected by ACH with concomitant GPP (S0125 and S0128 in Table 1 ), who were previously exome sequenced by our group. 6 The combined data set was filtered for removal of all synonymous changes and all polymorphisms occurring with >1% frequency in the 1000 Genomes CEU (Utah residents with ancestry from northern and western Europe) data set, the NHLBI Exome Sequencing Project Exome Variant Server, or 1,360 exomes sequenced in house. This identified an average of 485 protein-altering changes per sample (Table S2) . No gene harbored rare homozygous or compoundheterozygous alleles in more than one affected individual. Conversely, 13 loci showed heterozygous changes in four out of nine subjects (Table S3 ). The use of pathogenicity-prediction software (SIFT 12 and PolyPhen-2 13 for coding alleles and MaxEntScan 14 and Spliceman 15 for splicing variants)
indicated that only two genes, AP1S3 and MYOM1 (MIM 603508), encompassed variation classified as deleterious S0125  female  British  no  yes  10   S0128  female  British  no  yes  45   S0655  female  Polish  yes  no  57   S0656  female  Swiss  yes  no  76   S0657  female  Swiss  no  no  82   S0658  male  Swiss  no  no  49   S0659  female  Irish  no  no  54   S0660  female  Swiss  yes  no  56   S0661  female  British  no  no  39 All subjects were negative for mutations in IL36RN and CARD14, a locus that has been tentatively implicated in the pathogenesis of GPP. 9 Individuals S0125 and S0128 had been previously exome sequenced by our group. by multiple algorithms. Given that the four subjects bearing an AP1S3 variant all carried the same rare allele (c.97C>T [p.Arg33Trp]), we selected this locus for follow-up. We screened 119 unrelated British individuals (112 with PPP, five with GPP, and two with ACH; Tables S4 and S5) and detected the c.97C>T allele in five additional subjects (four with PPP and one with GPP). Moreover, we identified six subjects (five with PPP and one with GPP) who harbored a c.11T>G (p.Phe4Cys) mutation ( Figure 1B and 1C) . Thus, AP1S3 variants were found in all forms of pustular psoriasis but were noticeably enriched among ACH-affected subjects and significantly underrepresented within the PPP data set (Tables S6 and S7) .
To further explore the significance of these results, we assessed the frequency and pathogenic potential of the rare AP1S3 alleles observed in 1,695 unrelated control individuals (Table S8 ). Although we observed seven coding variants occurring with <1% frequency, we found that c.11T>G and c.97C>T were the only changes predicted to be pathogenic. Importantly, the frequencies of both alleles were significantly higher in pustular psoriasis subjects than in the general population: the c.11T>G mutation appeared in 2.3% of affected individuals, but only 0.6% of control subjects (p ¼ 0.01), and c.97C>T appeared in 3.6% of affected individuals, but only 0.7% of control subjects (p ¼ 2.3 3 10 À5 ). The combined analysis of the two mutations yielded p ¼ 2.5 3 10 À7 (Table 2) , exceeding the threshold for exome-wide significance (p < 2.5 3 10 À6 ). 16 To investigate whether AP1S3 mutations were also found in individuals of non-European descent, we analyzed 72 Asian (all with GPP) and four African (two with ACH and two with GPP) subjects. In keeping with the population frequencies documented by the 1000 Genomes Project, we found that none of the above subjects carried the c.11T>G or c.97C>T allele. We observed no other AP1S3 coding variant, with the exception of a heterozygous c.370C>G (p.Gln124Glu) mutation, found in a single Malay subject and predicted to be benign. Thus, our findings indicate that pustular psoriasis is specifically associated with the c.11T>G and c.97C>T alleles.
We next sought to determine whether the two mutations were the result of a founder effect. Because the late age of disease onset hindered the collection of parental samples, we focused our analysis on the affected subjects, whom we genotyped for a highly polymorphic intragenic (TG) repeat. We found that all c.97C>T subjects were heterozygous for a 214 bp allele, whereas all c.11T>G individuals carried a 218 bp repeat. Given the low population frequency of the 214 and 218 bp alleles, this observation strongly suggests that c.97C>T and c.11T>G are founder mutations and argues against the possibility of de novo inheritance (Table 3 ). In keeping with these findings, segregation analyses carried out in two representative pedigrees confirmed that the probands (T002206 and T001882, bearing c.11T>G and c.97C>T, respectively) had inherited the disease allele from an unaffected parent. Thus, the lack of family history among subjects with AP1S3 mutations (Table S6 ) is likely to reflect the requirement of environmental triggers for disease development. Indeed, it is well recognized that pustular flares are often initiated by infections, pregnancy, or drug exposure. 4 To explore the consequences of the p.Phe4Cys (c.11T>G) and p.Arg33Trp (c.97C>T) changes, we modeled the structure of AP-1 subunit s1C (encoded by AP1S3) with the Modeler 9 (v.8.0) package. 17 We used the T-Coffee software (v.1.0) 18 to align the sequence of AP-1 Variants were designated as damaging when a high-confidence pathogenicity prediction was returned by at least four out of five programs. All pathogenicity predictions are based on the analysis of AP1S3 transcript ENST00000396654. b The differences in total allele counts reflect the varying coverage of the relevant nucleotides in the control individuals who were exome sequenced.
subunit s1C with that of the murine AP-1 core 19 (Protein Data Bank ID 1W63), generating 200 models. We selected those with the best Modeler DOPE scores and visualized the p.Phe4Cys and p.Arg33Trp substitutions by using PyMol (v.1.3 Schrödinger). We also modeled the interaction between AP-1 subunit s1C and its partner m1A by superimposing human s1C coordinates on the structure of the murine AP-1 s1C/m1A crystal complex. We found that Phe4 is located within the core of AP-1 subunit s1C and is part of a cluster of hydrophobic residues, which stabilize the protein and its fold ( Figure 2A , top panel). Importantly, the p.Phe4Cys substitution causes the loss of crucial contacts with residues Ile35 and Trp52 and has a likely detrimental effect on the stability of the complex (Figure 2A, bottom panel) . We further observed that Arg33 is critically located at the AP-1 s1C/m1A interface, where the substitution of a positively charged arginine with a nonpolar tryptophan is likely to disrupt a salt bridge with Glu232 of AP-1 subunit m1A and substantially weaken the interaction between the two subunits ( Figure 2B ). In keeping with these predictions, we observed decreased levels of the p.Phe4Cys protein upon transfection of mutant and wild-type (WT) constructs into human embryonic kidney 293 (HEK293) and HaCaT cells. This reduction in AP-1 subunit s1C accumulation was not observed when a construct encoding the p.Arg33Trp change was transfected, supporting the notion that the p.Phe4Cys substitution specifically disrupts protein stability and folding, whereas p.Arg33Trp is more likely to exert its effect on protein-protein interactions ( Figures 2C, 2D , and S1).
Given that AP-1 subunit s1C is one of the core subunits thought to stabilize AP-1 heterotetramers, 3 we reasoned that p.Phe4Cys and p.Arg33Trp are likely to be loss-offunction changes disrupting the formation of functional AP-1 complexes. Given that the endosomal localization of the innate receptors TLR-7 and TLR-9 is dependent on AP-2 and AP-4, 21 we further hypothesized that AP-1 might be required for the trafficking of the paralog TLR-3 receptor. Thus, we proposed that AP1S3 deficiency would disrupt TLR-3 translocation to the endosome and result in abnormal downstream signaling.
To explore this hypothesis, we generated two stable AP1S3-knockdown cell lines ( Figure 3A ) through the lentiviral transduction of HaCaT immortalized keratinocytes with targeted small hairpin RNA (shRNA) constructs (Table S9 ). Because TLR-3 is cleaved by acidic proteases upon reaching the endosomes, 22 we investigated the effects of AP1S3 silencing by monitoring the levels of full-length and processed receptor. We found that TLR-3 trafficking was disrupted in both knockdown cell lines, where the ratio between endosomal and newly synthesized receptor was markedly reduced. This effect was already noticeable under basal conditions but became more pronounced upon stimulation of TLR-3 with the poly(I:C) ligand ( Figure 3B, lanes 2, 4, and 6 ).
To further explore these findings, we sought to determine whether AP1S3 deficiency also affects TLR-3-dependent induction of genes encoding type I interferons (IFNs). We stimulated control and knockdown cell lines with poly(I:C) and measured IFNB1 expression by realtime PCR. In keeping with the results of the previous experiments, we found that the induction of IFNB1 transcripts was virtually abolished in one knockdown cell line and significantly reduced in the second ( Figure 3C ).
Having demonstrated that AP1S3 knockdown disrupts TLR-3 endosomal translocation, we sought to determine whether disease-associated alleles have a similar impact. We reasoned that the p.Phe4Cys change would very likely mimic the effects of gene silencing, given its deleterious impact on protein stability. We therefore focused our attention on the c.97C>T (p.Arg33Trp) mutation. We generated another AP1S3-knockdown cell line by silencing gene expression in HEK293 cells ( Figure 3D ). In keeping with the results obtained in HaCaT keratinocytes, we were able to show that AP1S3 deficiency resulted in reduced processing of transfected TLR-3 ( Figure 3E , left panel). Having validated this experimental system, we investigated the effects of overexpressing WT versus mutant constructs. We found that the transfection of cDNAs encoding the p.Arg33Trp substitution resulted in decreased accumulation of N-ter TLR-3 ( Figure 3E , right panel), demonstrating a significant impact on protein function for this disease allele.
The devastating consequences of AP-1 deficiency have been documented in mice 3 and in humans, where recessive truncating mutations in AP1S1 cause MEDNIK syndrome (mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratodermas [MIM 609313]), a congenital multisystem disorder associated with reduced life expectancy. 23 Thus, the pleiotropic effects of AP-1 deficiency have hindered the identification of specific cellular processes that are controlled by this complex. Although the knockout of genes encoding AP-2 subunits is also embryonically lethal, 3 heterozygous missense mutations in AP2S1 (MIM 602242; encoding AP-2 subunit s2) have been associated with reduced calcium-sensing receptor endocytosis, which leads to familial hypocalciuric hypercalcemia (MIM 600740). 24 This suggests that the characterization of missense changes in genes encoding AP-1 and AP-2 could help dissect the cellular pathways that are affected by the disruption of each AP complex. Here, we describe two heterozygous AP1S3 mutations resulting in severe skin autoinflammation. Our analysis of 128 European and 76 non-European affected individuals has demonstrated that the disease is specifically associated with substitutions in residues Phe4 and Arg33, suggesting a crucial role for these two amino acids. This notion is supported by our structural biology findings and overexpression experiments, which indicate that p.Phe4Cys and p.Arg33Trp are likely to have a detrimental effect on AP-1 function.
To explore the consequences of AP-1 deficiency in skin, we silenced AP1S3 expression in HaCaT immortalized keratinocytes and HEK293 cells. We found that AP1S3 knockdown was consistently associated with a significant reduction in TLR-3 trafficking. Moreover, we demonstrated that TLR-3-mediated IFNB1 induction was markedly decreased in AP1S3-knockdown HaCaT keratinocytes. Importantly, IFN-b (the cytokine encoded by IFNB1) has well-documented anti-inflammatory functions, as demonstrated by its protective effect in several autoimmune conditions. 25, 26 IFN-b also downregulates the production of interleukin-1 (IL-1), 25 the cytokine driving the pathogenesis of most autoinflammatory conditions. 27 Thus, , orange) proteins. AP-1 s1C residues Arg33 and Trp33, together with AP-1 s1A residue Glu232 (which lies within 6 Å of Arg33), are shown in stick representation. (C) Immunoblot demonstrating the reduced accumulation of p.Phe4Cys proteins. WT and mutant pcDNA3.1-Myc-AP1S3 constructs were transfected alongside a pcDNA3.1-Myc-RNF114 plasmid (which was used as a transfection-efficiency and loading control) into HEK293 cells. Protein extracts were analyzed by immunoblot with an anti-Myc antibody (MA1-21316, 1:1,000 dilution, Thermo Scientific). The image is representative of the results obtained in two independent transfections. (D) Densitometric analysis of the immunoblots described in (C). The ratio between the intensities of the AP-1 s1C and RNF114 bands was derived with ImageJ. 20 Data are shown as means 5 SD of two independent experiments. *p < 0.05 (unpaired t test).
our findings raise the intriguing possibility that the reduced IFN response associated with AP1S3 mutations results in enhanced IL-1 production upon exposure to inflammatory stimuli. Of interest, none of the exomesequenced subjects lacking AP1S3 mutations carried any rare variants in other genes encoding AP-1 subunits, indicating that defects in other components of the complex might have distinct phenotypic consequences. Given the variety of cargoes that are trafficked by the AP-1 complex, alleles associated with pustular psoriasis are likely to affect the localization of additional molecules other than TLR-3. In fact, experiments carried out in HeLa cells have demonstrated that AP-1 depletion causes the deficiency of numerous proteins contributing to epidermal homeostasis (e.g., desmoplakin and clathrin interactor 1) and neutrophil function (e.g., PTPN9 and VPS45). 28 Thus, fully characterizing the impact of AP1S3 mutations on immune responses will require additional in vitro and ex vivo studies. Given that treatment with IL-1 blockers appears to be beneficial in at least some cases of pustular psoriasis, 29, 30 experiments focusing on IL-1 signaling deregulation would be of particular interest because they could deliver important insights into the workings of a druggable disease pathway. 5 cells) transfected with 10 mg packaging plasmids (2 mg VSV-G and 8 mg p8.91, Addgene 8454 and 8455) and 2 mg control (ctr; nonsilencing) or silencing shRNA construct. After selection in 10 mg/ml puromycin, the knockdown efficiency was measured by real-time PCR (Table S5) 
